NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM
Updated: Jun 17, 2022
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
Sponsor
ClinicalTrials.gov Identifier: NCT03464916
Official Title: A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : March 14, 2018
Click here to see details on ClinicalTrials.gov
Biological: CAR2 Anti-CD38 A2 CAR-T Cells
Autologous Anti-CD38 A2 CAR2-expressing T-cells (Code C156170)
Autologous Anti-CD38 A2 CAR2 T-cells
Autologous Anti-CD38 A2 CAR2-expressing T-cells
Autologous CAR2 Anti-CD38 A2 CAR T-cells
Autologous CAR2 Anti-CD38 A2 T-lymphocytes
Autologous CD38-A2 CAR2-expressing T-lymphocytes
Locations
United States, Florida
United States, Minnesota
United States, New York
United States, Pennsylvania